Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ
Pathobiology · 2022 · 89 (6) · 382-392
DOI: 10.1159/000522244 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathobiology, online erschienen am 09.05.2022. Verfasst von Islam M Miligy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer and Stem Cells, Nottingham Breast Cancer Research Centre, School of Medicine, Nottingham City Hospital, The University of Nottingh…. Hauptthemen laut MEDLINE: Aurora Kinase A, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Introduction
Aurora Kinase A (AURKA/STK15) has a role in centrosome duplication and is a regulator of mitotic cell proliferation. It is over-expressed in breast cancer and other cancers, however; its role in ductal carcinoma in situ (DCIS) remains to be defined. This study aims to characterize AURKA protein expression in DCIS and evaluate its prognostic significance.
Methods
AURKA was assessed immunohistochemically in a large well-characterized cohort of DCIS (n = 776 pure DCIS and 239 DCIS associated with invasive breast cancer [DCIS-mixed]) with long-term follow-up data (median = 105 months) and basic molecular characterization.
Results
High AURKA expression was observed in 15% of DCIS cases and was associated with features of aggressiveness including larger tumour size, high nuclear grade, hormone receptor negativity, HER2 positivity, and high Ki67 proliferation index. AURKA expression was higher in DCIS associated with invasive breast cancer than in pure DCIS (p < 0.0001). In the DCIS-mixed cohort, the invasive component showed higher AURKA expression than the DCIS component (p < 0.0001). Outcome analysis revealed that AURKA was a predictor of invasive recurrence (p = 0.002).
Conclusion
High AURKA expression is associated with poor prognosis in DCIS and might be a potential marker to predict DCIS progression to invasive disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cancer and Stem Cells, Nottingham Breast Cancer Research Centre, School of Medicine, Nottingham City Hospital, The University of Nottingham, Nottingham, UK, islam.miligy@med.menofia.edu.eg.
- Histopathology Department, Faculty of Medicine, Menoufia University, Shebeen El-Kom, Egypt, islam.miligy@med.menofia.edu.eg.
- Division of Cancer and Stem Cells, Nottingham Breast Cancer Research Centre, School of Medicine, Nottingham City Hospital, The University of Nottingham, Nottingham, UK.
- Cancer Genomics Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
Zitieren
APA
Miligy, I. M., Toss, M. S., Gorringe, K. L., Ellis, I. O., Green, A. R., & Rakha, E. A. (2022). Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ. Pathobiology, 89(6), 382-392. https://doi.org/10.1159/000522244
Vancouver
Miligy IM, Toss MS, Gorringe KL, Ellis IO, Green AR, Rakha EA. Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ. Pathobiology. 2022;89(6):382-392. doi:10.1159/000522244
BibTeX
@article{Miligy2022,
author = {Miligy, Islam M and Toss, Michael S and Gorringe, Kylie L and Ellis, Ian O and Green, Andrew R and Rakha, Emad A},
title = {Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ},
journal = {Pathobiology},
year = {2022},
volume = {89},
number = {6},
pages = {382--392},
doi = {10.1159/000522244}
}
EUVIMED